Skip to Main Content

Good morning, folks, and how are you today? We are doing just fine, thank you. A delicious cool breeze is wafting through the sunny Pharmalot campus, where the short person is busy hovering over a laptop and our official mascot is chasing wildlife — bunnies, chipmunks, squirrels, what have you. As for us, we are doing the usual — firing up the coffee kettle to make cups of stimulation, reviewing our to-do list. Perhaps you can relate. In any event, here are some tidbits for your consumption. Hope today goes well and you stay safe. …

The Trump administration chose five companies as the most likely candidates to produce a Covid-19 vaccine, a critical step in White House efforts to deliver on its promise of starting widespread inoculation of Americans by the end of the year, The New York Times tells us. The five companies are Moderna (MRNA); the combination of Oxford University and AstraZeneca (AZN), Johnson & Johnson (JNJ), Merck (MRK), and Pfizer (PFE). Among those left out were Sanofi (SNY), Inovio Pharmaceuticals (INO), and Novavax (NVAX).


House Democrats are demanding details from the Trump administration about the terms of its contracts with drug makers to fund the development of a potential Covid-19 vaccine, The Hill tells us. In a letter to Department of Health and Human Services secretary Alex Azar, the chairs of the House Select Committee on the Coronavirus Crisis and House Oversight and Reform Committee said they want to know whether the contracts include provisions to ensure the vaccines or therapeutics are affordable.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!